Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Hematology"
DOI: 10.1007/s12185-022-03334-8
Abstract: Acute myeloid leukemia (AML) predominantly affects elderly adults, and its prognosis worsens with age. Treatment options for patients in Japan ineligible for intensive chemotherapy include cytarabine/aclarubicin ± granulocyte colony-stimulating factor (CA ± G), azacitidine (AZA), low-dose cytarabine (LDAC), targeted… read more here.
Keywords: intensive chemotherapy; japan ineligible; treatment; outcomes patients ... See more keywords